Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell; Kami J. Maddocks; Eva González-Barca; Wojciech Jurczak; Anna Marina Liberati; Sven De Vos; Zsolt Nagy; Aleš Obr; Gianluca Gaidano; Pau Abrisqueta; Nagesh Kalakonda; Marc André; Martin Dreyling; Tobias Menne; Olivier Tournilhac; Marinela Augustin; Andreas Rosenwald; Maren Dirnberger-Hertweck; Johannes Weirather; Sumeet Ambarkhane; Gilles Salles

doi:10.3324/haematol.2021.279802

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.279802. Online ahead of print.

Authors

Johannes Duell¹, Kami J. Maddocks², Eva González-Barca³, Wojciech Jurczak⁴, Anna Marina Liberati⁵, Sven De Vos⁶, Zsolt Nagy⁷, Aleš Obr⁸, Gianluca Gaidano⁹, Pau Abrisqueta¹⁰, Nagesh Kalakonda¹¹, Marc André¹², Martin Dreyling¹³, Tobias Menne¹⁴, Olivier Tournilhac¹⁵, Marinela Augustin¹⁶, Andreas Rosenwald¹⁷, Maren Dirnberger-Hertweck¹⁸, Johannes Weirather¹⁸, Sumeet Ambarkhane¹⁸, Gilles Salles¹⁹

Affiliations

¹ Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg.
² Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH.
³ Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona.
⁴ Maria Sklodowska-Curie National Research Institute of Oncology, Kraków.
⁵ Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni.
⁶ Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA.
⁷ 1st Department of Internal Medicine, Semmelweis University, Budapest.
⁸ Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic.
⁹ Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara.
¹⁰ Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona.
¹¹ Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool.
¹² Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir.
¹³ Department of Medicine III, LMU University Hospital, Munich.
¹⁴ Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne.
¹⁵ Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand.
¹⁶ Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg.
¹⁷ Institute of Pathology, University of Würzburg, Würzburg.
¹⁸ MorphoSys AG, Planegg.
¹⁹ Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon.

PMID: 34407608
DOI: 10.3324/haematol.2021.279802

Abstract

Not available.